

# Radek Spisek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12096277/publications.pdf>

Version: 2024-02-01

100  
papers

8,431  
citations

66234

42  
h-index

54797

84  
g-index

101  
all docs

101  
docs citations

101  
times ranked

11367  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	2.1	686
2	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
3	Detection of immunogenic cell death and its relevance for cancer therapy. <i>Cell Death and Disease</i> , 2020, 11, 1013.	2.7	466
4	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
5	Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response. <i>Cancer Research</i> , 2011, 71, 4821-4833.	0.4	355
6	Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. <i>Blood</i> , 2007, 109, 4839-4845.	0.6	348
7	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 588.	2.2	317
8	Combinatorial Strategies for the Induction of Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 187.	2.2	289
9	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>Oncolmmunology</i> , 2015, 4, e1008866.	2.1	237
10	Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2015, 4, e965570.	2.1	189
11	Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. <i>Journal of Experimental Medicine</i> , 2007, 204, 831-840.	4.2	175
12	Calreticulin and cancer. <i>Cell Research</i> , 2021, 31, 5-16.	5.7	174
13	Trial Watch: Toll-like receptor agonists in cancer immunotherapy. <i>Oncolmmunology</i> , 2018, 7, e1526250.	2.1	172
14	Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e968434.	2.1	160
15	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. <i>Oncolmmunology</i> , 2020, 9, 1703449.	2.1	156
16	High hydrostatic pressure induces immunogenic cell death in human tumor cells. <i>International Journal of Cancer</i> , 2014, 135, 1165-1177.	2.3	151
17	Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. <i>Clinical Immunology</i> , 2006, 120, 260-271.	1.4	140
18	Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. <i>Blood</i> , 2008, 112, 1308-1316.	0.6	136

#	ARTICLE	IF	CITATIONS
19	Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. <i>Frontiers in Immunology</i> , 2015, 6, 402.	2.2	135
20	Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. , 2018, 6, 139.		131
21	Trial watch: Peptide-based vaccines in anticancer therapy. <i>Oncolimmunology</i> , 2018, 7, e1511506.	2.1	121
22	Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 18192-18205.	0.8	111
23	Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. <i>Blood</i> , 2016, 128, 3113-3124.	0.6	107
24	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. <i>Oncolimmunology</i> , 2016, 5, e1088631.	2.1	104
25	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>Oncolimmunology</i> , 2015, 4, e1008814.	2.1	102
26	Glialin Fragments Induce Phenotypic and Functional Maturation of Human Dendritic Cells. <i>Journal of Immunology</i> , 2005, 175, 7038-7045.	0.4	94
27	Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications. <i>Frontiers in Immunology</i> , 2019, 10, 2393.	2.2	92
28	Dynamics of Tâ€cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory Tâ€cells. <i>International Journal of Cancer</i> , 2013, 132, 1070-1079.	2.3	89
29	Trial Watchâ€”Oncolytic viruses and cancer therapy. <i>Oncolimmunology</i> , 2016, 5, e1117740.	2.1	88
30	Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8+ T cells. , 2019, 7, 261.		82
31	Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 417-427.	2.0	81
32	Impaired Toll-like receptor 8â€mediated IL-6 and TNF-Î± production in antigen-presenting cells from patients with X-linked agammaglobulinemia. <i>Blood</i> , 2007, 109, 2553-2556.	0.6	80
33	Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. <i>Clinical Immunology</i> , 2009, 133, 69-77.	1.4	79
34	TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4820-4831.	3.2	71
35	Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. <i>Oncolimmunology</i> , 2018, 7, e1503032.	2.1	67
36	Maturation state of dendritic cells during the extracorporeal photopheresis and its relevance for the treatment of chronic graft-versus-host disease. <i>Transfusion</i> , 2006, 46, 55-65.	0.8	65

#	ARTICLE	IF	CITATIONS
37	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>Onc Immunology</i> , 2016, 5, e1214790.	2.1	64
38	Trial watch: Dendritic cell-based anticancer therapy. <i>Onc Immunology</i> , 2014, 3, e963424.	2.1	62
39	Trial watch: Immune checkpoint blockers for cancer therapy. <i>Onc Immunology</i> , 2017, 6, e1373237.	2.1	62
40	Towards a Better Way to Die with Chemotherapy: Role of Heat Shock Protein Exposure on Dying Tumor Cells. <i>Cell Cycle</i> , 2007, 6, 1962-1965.	1.3	59
41	NF- $\kappa$ B, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment. <i>Oncotarget</i> , 2015, 6, 14123-14138.	0.8	58
42	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. <i>Onc Immunology</i> , 2022, 11, .	2.1	54
43	Trial Watch“Immunistimulation with cytokines in cancer therapy. <i>Onc Immunology</i> , 2016, 5, e1115942.	2.1	52
44	Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. , 2019, 7, 312.		52
45	Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells. <i>Onc Immunology</i> , 2017, 6, e1311433.	2.1	47
46	Trial Watch“Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>Onc Immunology</i> , 2016, 5, e1149674.	2.1	46
47	Maturation of dendritic cells by bacterial immunomodulators. <i>Vaccine</i> , 2004, 22, 2761-2768.	1.7	42
48	Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: Their relationship to KRAS mutational status and disease recurrence. <i>Human Immunology</i> , 2011, 72, 1022-1028.	1.2	42
49	Kinetics of Toll-like receptor-4 splice variants expression in lipopolysaccharide-stimulated antigen presenting cells of healthy donors and patients with cystic fibrosis. <i>Microbes and Infection</i> , 2007, 9, 1359-1367.	1.0	40
50	Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. <i>Journal of Translational Medicine</i> , 2011, 9, 223.	1.8	38
51	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Onc Immunology</i> , 2018, 7, e1433982.	2.1	38
52	FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. <i>Clinical Immunology</i> , 2009, 131, 1-10.	1.4	36
53	Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 89-100.	2.0	36
54	Relevance of the chaperone-like protein calreticulin for the biological behavior and clinical outcome of cancer. <i>Immunology Letters</i> , 2018, 193, 25-34.	1.1	36

#	ARTICLE	IF	CITATIONS
55	Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients. <i>Oncolmmunology</i> , 2016, 5, e1102827.	2.1	35
56	Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. <i>International Journal of Oncology</i> , 2016, 48, 953-964.	1.4	33
57	Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients. <i>Haematologica</i> , 2020, 105, 1868-1878.	1.7	32
58	Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, 546.	3.4	32
59	Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death. <i>Oncolmmunology</i> , 2017, 6, e1258505.	2.1	30
60	Trial Watch: Adoptive cell transfer for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e1046673.	2.1	29
61	Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines. <i>Oncotarget</i> , 2016, 7, 46120-46126.	0.8	29
62	Transient exposure of dendritic cells to maturation stimuli is sufficient to induce complete phenotypic maturation while preserving their capacity to respond to subsequent restimulation. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 445-454.	2.0	27
63	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e1026531.	2.1	26
64	Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy. <i>PLoS ONE</i> , 2017, 12, e0171539.	1.1	26
65	High hydrostatic pressure in cancer immunotherapy and biomedicine. <i>Biotechnology Advances</i> , 2018, 36, 577-582.	6.0	26
66	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3053-3065.	3.2	26
67	Kinetics of dendritic cells reconstitution and costimulatory molecules expression after myeloablative allogeneic haematopoietic stem cell transplantation: Implications for the development of acute graft-versus host disease. <i>Clinical Immunology</i> , 2009, 131, 60-69.	1.4	25
68	Intensive physical activity increases peripheral blood dendritic cells. <i>Cellular Immunology</i> , 2010, 266, 40-45.	1.4	25
69	Combined CNS and pituitary involvement as a primary manifestation of Wegener granulomatosis. <i>Clinical Rheumatology</i> , 2006, 25, 739-742.	1.0	24
70	Bordetella Adenylate Cyclase Toxin Differentially Modulates Toll-Like Receptor-Stimulated Activation, Migration and T Cell Stimulatory Capacity of Dendritic Cells. <i>PLoS ONE</i> , 2014, 9, e104064.	1.1	22
71	High hydrostatic pressure affects antigenic pool in tumor cells: Implication for dendritic cell-based cancer immunotherapy. <i>Immunology Letters</i> , 2017, 187, 27-34.	1.1	20
72	Immunological Network in Head and Neck Squamous Cell Carcinoma—A Prognostic Tool Beyond HPV Status. <i>Frontiers in Oncology</i> , 2020, 10, 1701.	1.3	18

#	ARTICLE	IF	CITATIONS
73	Decreased dendritic cell numbers but increased TLR9-mediated interferon-alpha production in first degree relatives of type 1 diabetes patients. <i>Clinical Immunology</i> , 2014, 153, 49-55.	1.4	17
74	Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial. <i>Gynecologic Oncology</i> , 2021, 162, 652-660.	0.6	17
75	In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients. <i>Clinical Immunology</i> , 2007, 122, 18-27.	1.4	16
76	Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. , 2022, 10, e003190.		16
77	Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice. <i>OncImmunology</i> , 2017, 6, e1362528.	2.1	15
78	Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype. <i>Immunology Letters</i> , 2020, 219, 46-53.	1.1	14
79	Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1. <i>Oral Oncology</i> , 2018, 82, 75-82.	0.8	13
80	RNA-seq of macrophages of amoeboid or mesenchymal migratory phenotype due to specific structure of environment. <i>Scientific Data</i> , 2018, 5, 180198.	2.4	13
81	Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. <i>Trends in Cancer</i> , 2022, 8, 426-444.	3.8	13
82	Immunoprevention of Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 735-750.	0.9	12
83	Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group. <i>Journal of Thoracic Oncology</i> , 2017, 12, 249-257.	0.5	11
84	Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling. <i>Journal of Controlled Release</i> , 2021, 332, 563-580.	4.8	11
85	The cytokine milieu compromises functional capacity of tumor-infiltrating plasmacytoid dendritic cells in HPV-negative but not in HPV-positive HNSCC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2545-2557.	2.0	9
86	Myeloid - derived suppressor cells in Type 1 diabetes are an expanded population exhibiting diverse T-cell suppressor mechanisms. <i>PLoS ONE</i> , 2020, 15, e0242092.	1.1	9
87	Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs. <i>Immunology Letters</i> , 2014, 160, 39-49.	1.1	8
88	Immunoprevention of cancer: time to reconsider timing of vaccination against cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1689-1691.	1.1	6
89	Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100427.	0.7	5
90	Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death. <i>Methods in Enzymology</i> , 2020, 632, 15-25.	0.4	3

#	ARTICLE	IF	CITATIONS
91	Methods to assess DC-dependent priming of T cell responses by dying cells. <i>Methods in Enzymology</i> , 2020, 632, 55-65.	0.4	1
92	Impact of Tumour Cell Death on the Activation of Anti-tumour Immune Response. , 2009, , 347-370.		1
93	Tumour devascularisation as a potential immunotherapeutic strategy. <i>Oncolmunology</i> , 2019, 8, e1526614.	2.1	0
94	Assessment of NK cell-mediated cytotoxicity by flow cytometry after rapid, high-yield isolation from peripheral blood. <i>Methods in Enzymology</i> , 2020, 631, 277-287.	0.4	0
95	Differential Antigenic Targets of Anti-Tumor Immune Response and Selective Immunity to Stem Cell Associated Group B SOX Proteins in Preneoplastic Versus Malignant Gammopathy.. <i>Blood</i> , 2005, 106, 5116-5116.	0.6	0
96	Immunotherapy for prostate cancer. <i>Urologie Pro Praxi</i> , 2016, 17, 159-166.	0.0	0
97	Title is missing!. , 2020, 15, e0242092.		0
98	Title is missing!. , 2020, 15, e0242092.		0
99	Title is missing!. , 2020, 15, e0242092.		0
100	Title is missing!. , 2020, 15, e0242092.		0